# *An Educational Overview of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted)*

**SHINGRIX**
(ZOSTER VACCINE RECOMBINANT, ADJUVANTED)

PRESENTED BY:

Lisa Glasser
MD

Thursday, May 10, 2018
6:30 PM

Terracotta Red
2820 Hewitt Avenue
Everett, Washington
(425) 322-5132

FOR QUESTIONS OR TO RSVP, PLEASE CONTACT:

LORRAINE STARODUB:
lorraine.y.starodub@gsk.com
by 5/7/2018. RSVP is required.

PROGRAM CODE:

INT-0028774

## Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

## Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

**Please see additional Important Safety Information for SHINGRIX on next page and accompanying full Prescribing Information.**

**Please see next page for attendance information and requirements.**

## Important Safety Information (cont'd)

- Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
- Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
- SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

**Please Read:**

Attendance at this promotional program sponsored by GlaxoSmithKline ("GSK") is limited to Health Care Professionals only. Guests will not be accommodated. Please contact your GSK representative and RSVP by the date above if you would like to attend this program.

Some state laws prohibit GSK from providing meals to qualified Health Care Professionals. In particular, Vermont state law prohibits GSK from providing meals at this event to HCPs who "regularly practice" in the state of Vermont, or to their employees or agents, even if they primarily practice in another state. Under Vermont law, "regularly practices" means practicing at least periodically under contract with, or as an employee or owner of, a medical practice, health care facility, nursing home, hospital or university located in Vermont.

In addition, many employers (e.g. Hospitals, Teaching Institutions, the Federal Government, States and local governments) place restrictions on what their employees may accept from outside parties as a condition of employment. GSK respects these restrictions and asks that you limit your participation to those activities permitted by your employer.

Note that GSK is publicly disclosing information regarding the monetary value of meals and related expenses provided to you as an attendee at this program and will disclose information as required by federal or state laws.

Trademarks are owned by or licensed to the GSK group of companies.

gsk

©2018 GSK group of companies or its licensor.
Produced in USA. 1000969R0 March 2018

SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)